DrugPipeline.net has announced the addition of “Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020” research report to their website DrugPipeline.net

Bangalore, India -- (SBWire) -- 12/14/2016 --Immunomodulators are the drugs that help to regulate the immune system. These drugs either stimulate the weak immune systems or moderate the overactive immune systems. Though many drugs are available in the market, there still exists a huge unmet need in the autoimmune and inflammatory immunomodulators market as there are no medicines that provide complete cure to some diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn's disease.

Report forecast the global autoimmune and inflammatory immunomodulators market to grow at a CAGR of 7.01% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global autoimmune and inflammatory immunomodulators market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AbbVie
- Johnson & Johnson
- Amgen
- F. Hoffmann-La Roche
- Pfizer

Other prominent vendors
- AstraZeneca
- Avaxia Biologics
- Biogen Idec
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Eli Lilly
- Enlivex Therapeutics
- Gilead Sciences
- Immune Pharmaceuticals
- Merck
- Mitsubishi Tanabe Pharma
- Neovacs
- Prometheus Laboratories
- Sandoz
- Sanofi
- Swedish Orphan Biovitrum
- Takeda Pharmaceuticals
- UCB

Market driver
- Development of novel therapies using innovative technologies.
- For a full, detailed list, view our report

Market challenge
- Discontinuation of drugs under development leading to substantial loss in revenue.
- For a full, detailed list, view our report

Market trend
- Advent of biosimilars expected to improve the treatment rates.
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 98 pages "Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020" report covers Executive summary, Scope of the report, Market research methodology, Introduction, Autoimmune and inflammatory diseases, Pipeline portfolio, Market landscape, Market segmentation by type of disease, Market segmentation by molecule type, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Key vendor analysis, Appendix.

For more information Visit at: http://www.drugpipeline.net/technavio/global-autoimmune-and-inflammatory-immunomodulators-market-2016-2020

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.